Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001982434 | SCV002221186 | likely benign | Amyotrophic lateral sclerosis type 4; Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2023-08-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004043685 | SCV004947874 | uncertain significance | Inborn genetic diseases | 2023-10-16 | criteria provided, single submitter | clinical testing | The c.6805T>A (p.S2269T) alteration is located in exon 21 (coding exon 19) of the SETX gene. This alteration results from a T to A substitution at nucleotide position 6805, causing the serine (S) at amino acid position 2269 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004728977 | SCV005337184 | uncertain significance | SETX-related disorder | 2024-04-05 | no assertion criteria provided | clinical testing | The SETX c.6805T>A variant is predicted to result in the amino acid substitution p.Ser2269Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |